FIG.1



11G9.6
5B7
Mouse IgG2b,k
B cells
(CD19+)
Non-stimulation
CpG2006
(TLR9 ligand)
Cells
PLD4

FIG.2



Control
Mouse IgG1,k
PLD4
3B4
Non-stimulation
Stimulation with
CpG2006
(TLR9 ligand)
0.12
0.3
0.1
1.61
CD19

FIG.3



Mouse IgG2b,k
5B7
13D4
13H11
11G9.6
0.12
0.41
0.27
0.27
0.27
0.11
3.59
3.24
3.33
3.33
PLD4
CD19
Non-stimulation
Stimulation with CpG2006

FIG.4




No Ab
Control Ig
ch3B4
ch13D4
ch13H11
ch5B7
ch11G9.6
7.42
8.1
5.99
4.54
4.48
6.29
6.74
1.74
4.48
PLD4
CD19

FIG.5


Frequency of PLD4+ human activated B cells compared to control Ig-treated B cells (%)
100
80
60
40
20
0
93.3
100.0
25.8
66.4
No Ab
Control Ig
ch5B7
ch11G9.6



Frequency of PLD4+ human activated B cells compared to control Ig-treated B cells (%)
100
80
60
40
20
0
91.6
100.0
70.2
56.0
55.3
No Ab
Control Ig
ch3B4
ch13D4
ch13H11

FIG.6




Plasmablasts
(CD19+ CD27+ IgD- CD38+)
% of plasmablasts
100
80
60
40
20
0
Control Ig
ch3B4
ch5B7
ch13D4
ch13H11
ch11G9.6

FIG.7


human IgG production
human IgG (ng/ ml)
80
60
40
20
0
Control Ig
ch3B4
ch5B7
ch13D4
ch13H11
ch11G9.6